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Abstract
The receptors mediating the hemodynamic responses to cannabinoids are not
clearly defined due to the multifarious pharmacology of many commonly used
cannabinoid ligands. While both CB1 and TRPV1 receptors are implicated, G
protein-coupled receptor 55 (GPR55) may also mediate some of the hemody-
namic effects of several atypical cannabinoid ligands. The present studies
attempted to unravel the pharmacology underlying the in vivo hemodynamic
responses to ACEA (CB1 agonist), O-1602 (GPR55 agonist), AM251 (CB1
antagonist), and cannabidiol (CBD; GPR55 antagonist). Agonist and antagonist
profiles of each ligand were determined by ligand-induced GTPcS binding in
membrane preparations expressing rat and mouse CB1 and GPR55 receptors.
Blood pressure responses to ACEA and O-1602 were recorded in anesthetized
and conscious mice (wild type, CB1
/ and GPR55/) and rats in the absence
and presence of AM251 and CBD. ACEA demonstrated GTPcS activation at
both receptors, while O-1602 only activated GPR55. AM251 exhibited antago-
nist activity at CB1 and agonist activity at GPR55, while CBD demonstrated
selective antagonist activity at GPR55. The depressor response to ACEA was
blocked by AM251 and attenuated by CBD, while O-1602 did not induce a
depressor response. AM251 caused a depressor response that was absent in
GPR55/ mice but enhanced by CBD, while CBD caused a small vasodepres-
sor response that persisted in GPR55/ mice. Our findings show that assess-
ment of the pharmacological profile of receptor activation by cannabinoid
ligands in in vitro studies alongside in vivo functional studies is essential to
understand the role of cannabinoids in hemodynamic control.
Abbreviations
abn-CBD, abnormal cannabidiol; ACEA, arachidonyl-20-chloroethylamide; AEA,
anandamide; AM251, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperi-
din-1-yl)-1H-pyrazole-3-carboxamide; AM281, 1-(2,4-dichlorophenyl)-5-(4-iod-
ophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; BSA, bovine
serum albumin; CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; CBD,
cannabidiol; EDTA, ethylenediaminetetraacetic acid; GPR55, G protein coupled
receptor 55; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; LPI, lyso-
phosphatidylinositol; TRPV1, transient receptor potential vanilloid 1 receptor.
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Introduction
The in vivo cardiovascular effects of cannabinoids, the
most studied of which is the endocannabinoid ananda-
mide (AEA), are complex and vary substantially depend-
ing upon the experimental design and whether or not the
studies are performed in anesthetized or conscious ani-
mals (reviewed in Malinowska et al. 2012). Moreover,
responses are mediated through a mixture of direct vaso-
dilator effects on blood vessels, a reduced cardiac contrac-
tility, and modulation of autonomic control of both the
heart and the vasculature. In anesthetized rats, intrave-
nous (i.v.) administration of AEA elicits a three phase
blood pressure (BP) response involving the transient
receptor potential vanilloid-1 (TRPV1) receptors located
on sensory vagal nerves in the heart (phase 1 transient
depressor and phase 2 transient pressor responses) and
CB1 receptors present in the vasculature and myocardium
(phase 3 prolonged fall in BP; Varga et al. 1996; Lake
et al. 1997; Malinowska et al. 2001). In contrast, in con-
scious normotensive rats, AEA causes a pressor response
(Gardiner et al. 2002), whilst in conscious spontaneously
hypertensive rats (SHR) the initial two phases of the clas-
sical three phase response are followed by prolonged
vasodilation (Ho and Gardiner 2009).
However, there are studies that suggest other receptors
are involved in mediating these responses, and this also
holds true for other cannabinoid ligands. For example,
evidence exists for the presence of an endothelial
SR141716-sensitive non-CB1, non-CB2, non-vanilloid
receptor that is unresponsive to certain established CB1/
CB2 receptor agonists such as WIN-55,212-2, but can be
activated by both AEA and its stable analog methananda-
mide, as well as lipid conjugates such as virodhamine and
N-arachadonoylglycine (NAGly) (Ho and Hiley 2004;
Parmar and Ho 2010). A further receptor that has been
proposed to be activated by AEA is the G-protein-coupled
receptor 55 (GPR55), which belongs to a group of rho-
dopsin-like seven transmembrane/G-protein-coupled
receptors and was originally isolated in human caudate
nucleus (Sawzdargo et al. 1999). Some of our group (Ry-
berg et al. 2007) were the first to describe the ligand
pharmacology of this receptor and demonstrated that
AEA, virodhamine, the abnormal cannabidiol (abn-CBD;
a synthetic regioisomer of CBD), and its synthetic analog,
O-1602 all bind to and activate the receptor in vitro,
findings that have been corroborated by further studies
(e.g., Waldeck-Weiermair et al. 2008), thus adding sup-
port to the proposal that GPR55 is a putative third can-
nabinoid receptor (Baker et al. 2006; Pertwee 2007).
While the receptors involved in mediating BP responses
to endocannabinoids remain to be determined, the
picture is further complicated by the complex and multi-
farious pharmacology of the compounds used as experi-
mental tools to address the question. For example,
AM251 was originally described as a selective CB1 antago-
nist (reviewed in Howlett et al. 2002), but it is now rec-
ognized that it also acts as a GPR55 agonist (Ryberg et al.
2007; Pertwee et al. 2010). In addition, the phytocannabi-
noid CBD has routinely been used as a GPR55 antagonist
(Ryberg et al. 2007), yet it also demonstrates activity at
various other receptors (Pertwee 2008; Pertwee et al.
2010). Similarly O-1602, which was initially regarded and
utilized as a GPR55 agonist since its actions can be
blocked by CBD (Jarai et al. 1999)is now thought to exert
equipotent action at another orphan cannabinoid candi-
date receptor (GPR18; McHugh et al. 2010).
Most previous studies have focused on either the in vi-
tro assessment of the ability of ligands to bind to CB1 or
GPR55 receptors and activate downstream signaling pro-
cesses (e.g., Ryberg et al. 2007; Pertwee et al. 2010; Hens-
tridge et al. 2011) or on their vascular functional
responses (e.g., Wagner et al. 1999; Ho and Hiley 2003,
2004), but rarely both. Therefore, this study was per-
formed to first determine the receptor profiles of CBD,
AM251, O-1602, and the CB1 agonist arachidonyl-2
0-chlo-
roethylamide (ACEA) using a GTPcS-binding assay in
membrane preparations exclusively expressing recombi-
nant CB1 or GPR55 receptors. Once receptor profiles
were identified, we then studied the hemodynamic
responses to each of these compounds in both anesthe-
tized and conscious rats and mice, using wild type, CB1,
and GPR55 knockout mice, to determine whether the
in vivo hemodynamic profiles correlated with the activa-
tion profiles determined in vitro.
Materials and Methods
Assessment of ligand-induced GTPcS binding
in membrane preparations expressing rat
and mouse CB1 and GPR55 receptors
HEK293s cells were transiently transfected with cDNA
encoding rat or mouse CB1 or GPR55 and membranes were
prepared as previously described (Ryberg et al. 2007). In
short, agonist activities in [35S]-GTPcS binding assays were
determined by the addition of ligand at 30°C for 45 min in
membrane buffer [50 mmol/L NaCl, 5 mmol/L MgCl2,
0.5 mmol/L EDTA, 25 mmol/L HEPES (all Sigma, Gilling-
ham, Dorset, UK); pH 7.4] containing 0.05 lg lL1 of
membrane protein with 0.01% BSA, 25 lmol/L guanosine
50-diphosphate (GDP), 100 lmol/L dithiothreitol (DTT),
and 0.53 nmol/L [35S]GTPcS (PerkinElmer) in a final vol-
ume of 200 lL. Antagonist assays were performed similarly,
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with the addition of an EC80 concentration of CP55940 as a
nonselective CB1/CB2 agonist in conjunction with the ligand
to be tested. Nonspecific binding was determined in the
presence of 20 lmol/L unlabeled GTPcS. The reaction was
terminated by addition of ice-cold wash buffer (50 mmol/L
Tris-HCl, 5 mmol/L MgCl2, 50 mmol/L NaCl; pH 7.4) fol-
lowed by rapid filtration under vacuum through 96-well B-
glass fiber filter plates (PerkinElmer, Waltham, Massachu-
setts, USA) using a Biomek FX (Beckman Coulter, Bromma,
Sweden). The filter plates were dried (30 min at 50°C)
before scintillation liquid (PerkinElmer) was added onto the
filters and the bound radioactivity was determined using a
scintillation counter (Wallac). Data were fitted with a four-
parameter logistic fit using the equation y = A + (B  A)/
1 + ((C/x)^D), where A is no activation, B is full activation,
C is the EC50, and D is the Hill slope. All data were based
on at least three independent experiments.
In vivo studies
Animals
All procedures were performed under either a Project
Licence issued under the UK Animals (Scientific Proce-
dures) Act 1986 (procedures under terminal anesthesia)
or under the approval of the local Ethical committee in
Gothenburg (conscious studies). The studies were
designed to comply with the ARRIVE Guidelines for
reporting in vivo studies (Kilkenny et al. 2010). Normo-
tensive Sprague–Dawley (SD) rats and SHR were pur-
chased from Charles River (Tranent, Scotland, UK). CB1
knockout (CB1
/) mice and their corresponding wild-
type (WT; C57Bl/6J) control were bred at AstraZeneca
(AZ) from founder pairs obtained from Dr. Andreas Zim-
mer, Germany (Zimmer et al. 1999). GPR55 knockout
(GPR55/) mice were bred at both AZ and the Univer-
sity of Aberdeen from heterozygous GPR55 knockout
mice, which were intermated to generate F1 mice homo-
zygous for the GPR55 mutation (GPR55/) and WT
(C57Bl/6J) littermate controls. Both males and females
were used and genotyped as previously described (Whyte
et al., 2009). Neither genetically modified strain demon-
strated any obvious phenotypic difference from WT ani-
mals. All animals were group housed in cages at a
temperature of 21  2°C and 55  10% humidity with a
12 h light/dark cycle and allowed free access to food and
tap water.
Hemodynamic studies in anesthetized rats and
mice
All experiments performed under terminal anesthesia
were carried out following approval by Robert Gordon
University Animal Ethics Panel. Anesthesia was induced
in male SD rats (200–300 g) by sodium pentobarbital
[60 mg kg1 intraperitoneal (i.p.) injection]. Male/female
WT and GPR55/ mice (25–35 g) were anesthetized
with a mixture of ketamine (120 mg kg1) and xylazine
(16 mg kg1) via i.p. injection. For both species the tra-
chea was cannulated to allow artificial respiration with
room air when required (54 strokes min1 and tidal vol-
ume 1.5 mL 100 g1 for rats; 120 strokes min1 and tidal
volume 100 lL 10 g1 for mice) and the left carotid
artery and right jugular vein were cannulated for the mea-
surement of arterial BP (MLT844 Physiological Pressure
Transducer; AD Instruments, Oxford, UK) and drug
administration, respectively. Core temperature was moni-
tored continuously and maintained at 37–38°C with the
aid of a Vetcare heated pad (Harvard Apparatus Ltd.,
Boston, Massachusetts, USA). Anesthesia was monitored
by foot pinch reflex and maintained throughout by
administration of additional doses of anesthetic (rats: 3–
4 mg kg1 of sodium pentobarbital salt i.v.; mice: 50 lL
25 g1of ketamine/xylazine i.p.) every 40 min, or as
required. Both mean arterial blood pressure (MABP) and
a standard limb lead I electrocardiogram (ECG) were
monitored continuously throughout the experimental per-
iod using a Power Lab data acquisition system via a
Bridge Amplifier and Animal Bio Amplifier, respectively,
and data subsequently analyzed using Chart Software (all
AD Instruments). Heart rate (HR) was calculated from
the ECG and recorded throughout the entire experimental
period. After a stabilization period of approximately
15 min dose–response experiments were carried out as
described below.
Blood pressure measurements in conscious rats
and mice
All studies in conscious animals were performed in SHR.
Following anesthesia with isoflurane (4% in air followed
by 2% during surgery) with supplemental Romefen
(10 mg kg1 s.c.; Merial SAS, Lyon, France) for analgesia,
a polyethylene catheter (PE10) was inserted into the
abdominal aorta, proximal to the kidneys, for BP record-
ing, and a silicon catheter (SEDAT, Irigny, France) was
inserted into the jugular vein for drug administration.
Both catheters were tunneled subcutaneously to the neck
region and anchored to an inert button. Immediately after
completion of surgery the rats were connected to a teth-
ered swivel system with a continuous intra-arterial infu-
sion (700 lL h1) of 0.9% NaCl containing melagatran
(10 mg L1) in order to keep the arterial line open. The
anesthetic and surgical procedures for the CB1
/,
GPR55/, and WT mice used for the studies in con-
scious animals were identical to those in the rat, with the
ª 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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exception that the arterial catheter was placed in the
descending aorta via the carotid artery. Following the
completion of surgery, the animals were allowed to
recover for 24 h with free access to food and water. Dur-
ing the experiments, both BP and HR were recorded con-
tinuously in conscious animals and data fed into in-house
software (v.4.0; PharmLab), reporting average values of
MABP, systolic, diastolic, and pulse pressures, HR and
body temperature every 15 sec.
Experimental protocols
Assessment of the hemodynamic responses to
ACEA in the absence and presence of AM251 and
CBD
As a preliminary assessment of the effects of ACEA on
arterial BP, a single bolus intravenous dose (3 mg kg1;
selected from the literature as a dose known to produce a
depressor response) was given to anesthetized rats. This
was then repeated in the presence of AM251 (1 and
3 mg kg1), CBD (50 lg kg1) or a combination of the
two to establish their ability to influence the response to
ACEA (See Fig. 1 for the Experimental Protocol). Since
the data from the GTPcS-binding assay (Table 1) demon-
strated ACEA to exhibit activity at GPR55 within the
nanomolar range (and only one order of magnitude
higher than at CB1 receptors) we also explored the role of
GPR55 in the depressor response to ACEA in anesthetized
WT and GPR55/ mice using the same experimental
protocol as that described for the anesthetized rats
(Fig. 1). To account for any vehicle effects, all responses
to ACEA were assessed either in the presence of these
antagonists or their vehicles (CBD dissolved in ethanol;
AM251 dissolved in a mixture of DMSO and Tween 80;
both were diluted with saline prior to drug administra-
tion; Fig. 1). The time interval between drug administra-
tions was 10–15 min to allow BP values to return to
predrug values.
Assessment of the hemodynamic responses to O-
1602
Using an identical protocol to that used for ACEA, the
effect of O-1602 (5–100 ng kg1 administered as incre-
mental i.v. doses) was determined on HR and BP in anes-
thetized rats (in the absence and presence of AM251 and/
or CBD) and in anesthetized WT and GPR55/ mice.
Since we were unable to observe any hemodynamic
responses to O-1602 compared to vehicle (methyl acetate)
in anesthetized animals, these experiments were repeated
in conscious mice to abrogate any effects of anesthesia on
the hemodynamic responses, using a higher dose range of
O-1602 (5, 10 and 15 mg kg1 i.v.). To determine any
role for CB1and GPR55, these experiments were per-
formed in WT, GPR55/ and CB1
/mice; for the stud-
ies in WT and CB1
/ mice, responses to O-1602 were
determined in the absence (vehicle) and presence of CBD
(5 mg kg1), whereas in the GPR55/ mice responses
were determined in the absence (vehicle) and presence of
the CB1 antagonist AM281 (10 mg kg
1). Finally, since
the cardiovascular effects of cannabinoids can be exagger-
ated in hypertension (Ho and Gardiner 2009), we investi-
gated whether a depressor response to O-1602 could be
unmasked in the setting of elevated MABP and intact
autonomic vascular control by using SHR’s pretreated
with metoprolol (10 mg kg1 i.v.), to prevent barorecep-
tor reflex correction of changes in BP.
Assessment of the hemodynamic responses to
AM251 and CBD
Although the study was originally designed to determine
the ability of CBD and AM251 to block the depressor
responses to ACEA and O-1602, both CBD and AM251
were found to produce depressor responses themselves
which were worthy of study, particularly since AM251 has
been reported to possess pharmacological actions at both
CB1 (as an antagonist) and GPR55 (as an agonist) recep-
tors (Ryberg et al. 2007; reviewed in Stanley et al.
2012).For CBD, anesthetized rats and mice (both WT and
GPR55/) were administered a single bolus dose of CBD
(50 lg kg1). For AM251 similar experiments were per-
formed, but in the absence and presence of CBD to deter-
mine whether CBD mimicked the effects of GPR55
deletion.
Measurement of hemodynamic responses and
statistical analyses
In order to take account of any vehicle responses and
variations in the time course of the responses to the vari-
ous cannabinoid ligands, a standard approach was
adopted to measuring the BP responses in all experimen-
tal models. MABP measurements were taken every 15 sec
from 1 min prior to drug/vehicle until 10 min postdrug
administration. Changes in MABP at each sampling point
Figure 1. Experimental protocol for the assessment of the effects of AM251 on the depressor responses to ACEA in anesthetized rats and mice.
Experiments were performed in the absence (A) or presence (B) of CBD (50 lg kg1) in separate groups of animals. Examples of original traces
showing the blood pressure (top trace) and heart rate (bottom trace) responses to ACEA and its vehicle in rats (C) and mice (D).
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were calculated as a % change in MABP and time plots
used to calculate area above the curve (AAC) for depres-
sor responses or area under the curve (AUC) for pressor
responses. Data were expressed as mean  SEM. and
MABP responses compared directly by either a paired t-
test (responses within animals) or by two-way analysis of
variance (ANOVA) followed by Bonferroni post hoc test
(for comparing multiple drug interventions across several
groups). All drug responses were compared directly with
the vehicle responses to determine the exact magnitude of
the response to the ligand.
Results
[35S]-GTPcS binding assays
The EC50 data for all of the ligands used in the [
35S]-GTPcS
binding assays are shown in Table 1. ACEA demonstrated
GTPcS binding at both receptors, with an approximately
10-fold higher affinity for CB1 in both mouse and rat tissue
as compared to GPR55.O-1602-activated GPR55 with a
potency approximately 5 times that of ACEA. AM251
exhibited significant activity at both CB1 (as an antagonist)
and GPR55 (as an agonist), with only a three to five-fold
higher potency for CB1. In contrast, AM281 demonstrated
antagonist activity selectively for CB1 and CBD demon-
strated selective antagonism at GPR55. For comparison,
AEA was also included in the binding assay and exhibited
similar activity at both CB1 and GPR55 in the low nanomo-
lar range consistent with previous findings for the human
receptor (Ryberg et al. 2007). In conclusion, there were no
significant species differences in EC50 values for either
receptor for any of the ligands tested.
Hemodynamic responses to ACEA in
normotensive anesthetized rats and mice
A single bolus dose of ACEA (3 mg kg1) produced a
reproducible and pronounced depressor response in anes-
thetized rats (P < 0.001; Figs. 2A and E), but had no effect
on HR (Fig. 2C). The magnitude and duration of the
response to ACEA was attenuated by AM251 (1 and
3 mg kg1) in a dose-dependent manner (P < 0.01;
Figs. 2A and E). In the presence of CBD alone
(50 lg kg1) the duration of the response to ACEA was
blunted and consequently the AAC value was reduced by
approximately 50% (P < 0.05; Figs. 2B and E). Combined
administration of CBD followed by AM251 5 min later, did
not produce an additive blockade of the ACEA response;
indeed the blockade seen with the higher dose of AM251
was no longer evident (Fig. 2E). In contrast, ACEA did not
produce a depressor response in anesthetized mice that
could be distinguished from the response to the vehicle in
either WT (Fig. 3A) or GPR55/ (Fig. 3B) mice, nor was
there any measurable effect on HR (Figs. 3C and D).
Hemodynamic responses to O-1602
O-1602 (5–100 ng kg1) did not produce any changes in
MABP or HR in anesthetized rats (Figs. 4A, C, and E) or
WT mice (Figs. 4B, D, and F) over and above those seen
with the vehicle. In conscious hypertensive rats, O-1602
administered in three ascending doses (5, 10, and
20 mg kg1) spaced 20 min apart did not induce any
changes in MABP (Fig. 5A) or HR (Table 2), even though
O-1602 was given at much higher doses than those given to
anesthetized rats. However, CBD pretreatment revealed a
vasodepressor response to the lowest dose of O-1602
(Fig. 5B, Table 2) while co-administration of 10 mg kg1
AM281 (a more selective CB1 antagonist; Ryberg et al.
2007) revealed a marked vasodepressor response, which
was present for all doses and was sustained in the presence
of 5 mg kg1 CBD (Figs. 5C and D). None of the interven-
tions induced any changes in HR (Table 2).
In conscious WT mice, O-1602 had no effect on MABP
(Fig. 5A), but did induce a transient bradycardia at the
highest dose tested (Fig. 5B; Table 3). However, in CB1
/
mice a dose-dependent depressor response was observed
and the HR responses to O-1602 were markedly enhanced
(Figs. 6C and D; Table 3). Pretreatment with CBD also
Table 1. Ligand-dependent [35S]-GTPcS binding assays performed in membranes prepared from HEK293s cell transiently transfected with either
rat or mouse CB1 or GPR55 cDNA.
CB1 EC50 (nmol/L) GPR55 EC50 (nmol/L)
Compound Rat Mouse Rat Mouse
ACEA 7  1 3  0.5 78  4 62  3
O-1602 >30,000 >30,000 20  3 12  4
CBD >30,000 >30,000 624  13* 780  8*
AM251 26  8* 13  2* 74  3 68  3
AM281 13  4* 8  1* >30,000 >30,000
AEA 34  2 25  8 24  3 38  3
EC50 values are expressed as mean  SEM of at least three independent experiments. “*” indicates that the ligand behaved as an antagonist.
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unmasked a dose-dependent depressor response to O-1602
in WT mice (Fig. 6E; Table 3) and exacerbated the drug-
induced bradycardia (Fig. 6F; Table 3), but did not further
enhance the responses to O-1602 in CB1
/ mice (Figs. 7G
and H; Table 2). Finally, administration of O-1602 in the
presence of AM281 in GPR55/ mice did not elicit a
depressor response (Table S1).
Hemodynamic responses to CBD
CBD alone induced a small but measurable and statisti-
cally significant depressor response in anesthetized nor-
motensive rats (P < 0.05; Figs. 7A and B) and induced
depressor responses of a similar magnitude in WT and
GPR55/ mice (Figs. 7C–E); HR was unaffected in any
experiments (data not shown). AM251 on its own had no
effect in anesthetized rats, however, when given in the
presence of CBD it induced a depressor response (Fig. 8).
In contrast, AM251 alone induced a depressor response
in WT, but not GPR55/, mice that was similarly aug-
mented in the presence of CBD (Figs. 8C–E).
Discussion
GTPcS-binding profiles
The GTPcS-binding assay is a relatively simple and
straightforward assay that measures a functional conse-
(A) (B)
(D)
(E)
(C)
Figure 2. Hemodynamic responses to ACEA and its vehicle in normotensive anesthetized rats, showing the time course of the depressor responses
(expressed as a percentage fall in mean arterial blood pressure from baseline) in the absence (A) and presence (B) of CBD (50 lg kg1) and percent
changes in heart rate (C and D). Baseline MABP’s and HR’s for each group were control (129  4 mmHg and 379  8 bpm; n = 8) and CBD
(135  4 mmHg and 390  4 bpm; n = 8), respectively. Panel (E) summarizes the mean areas above the curve for the blood pressure response
(AAC in arbitrary units). All values shown are mean  SEM; *P < 0.01 versus vehicle (within group); #P < 0.05 versus ACEA (control group).
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quence of receptor activation at one of the earliest
receptor-mediated events and is used routinely to study
receptors coupled to G(i/o) proteins, but can also be
used with GPCRs that couple to the G(s) and G(q) fam-
ilies of G proteins (Harrison and Traynor 2003). Since
previous studies from our group have shown that activ-
ity of ligands at GPR55 and CB1 receptors can be mea-
sured using this assay (Ryberg et al. 2007), it was an
appropriate choice to explore the effects of the ligands
under study in CB1 and GPR55-transfected cells from
both animal species used for the in vivo studies (rat and
mouse). Consistent with reports of its action as a selec-
tive CB1 agonist (Hillard et al. 1999), ACEA demon-
strated activity at the CB1 receptor in the low
nanomolar range. However, ACEA also exhibited agonist
activity at GPR55 in the nanomolar range, which to our
knowledge is the first demonstration that this ligand also
activates GPR55. O-1602 was also found to exert agonist
activity at GPR55 in the nanomolar range, with no
activity at CB1. However, in light of the building evi-
dence to support the notion that O-1602 also activates
GPR18 it would have been of interest to also determine
the activation profile of O-1602 in cells expressing this
receptor.
In terms of the antagonist drugs, CBD showed activity
as an antagonist at GPR55, which is consistent with our
previous findings (Ryberg et al. 2007), albeit in the high
nanomolar range, and did not demonstrate any activity as
an agonist at CB1 receptors. Finally, as well as exhibiting
antagonist activity at CB1 receptors in the nanomolar
range, AM251 shows clear agonist activity at GPR55 in a
similar concentration range, which is consistent with the
literature (Pertwee et al. 2010). In contrast, the similar
molecule AM281 demonstrated antagonism of CB1 at
nanomolar concentrations whilst it had no activity as
either an agonist or antagonist at GPR55.
(A) (B)
(D)
(E)
(C)
Figure 3. The time course of the depressor responses (expressed as a percentage fall in mean arterial blood pressure from baseline) to ACEA and
its vehicle in WT (A) and GPR55/ (B) mice and percent changes in heart rate (C and D). Baseline MABP’s and HR’s for each group were WT
(89  3 mmHg and 329  6 bpm; n = 8) and GPR55/ (89  2 mmHg and 339  5 bpm; n = 8), respectively. Panel (E) summarizes the mean
areas above the curve for the blood pressure response (AAC in arbitrary units). All values shown are mean  SEM.
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Hemodynamic responses to ACEA
The finding that ACEA caused a marked fall in arterial
BP in anesthetized rats, which was blocked by AM251,
suggests a straightforward agonist/antagonist relationship
and is consistent with the GTPcS-binding data. Most pre-
vious studies showing CB1-mediated vasodilatation have
been undertaken in isolated blood vessel preparations and
have used the endocannabinoid, AEA, rather than ACEA,
as an agonist. However, ACEA has been shown to
decrease coronary perfusion pressure and increase coro-
nary flow (Ford et al. 2002) in isolated perfused hearts,
although confirmation of an action at CB1 receptors using
an appropriate antagonist was not reported. This is there-
fore the first study to demonstrate a CB1-mediated va-
sodepressor response with ACEA in vivo and that it can
be blocked by AM251.
However, while our data support the notion of CB1
receptors mediating a vasodepressor effect, it was interest-
ing to note that in anesthetized rats pretreated with CBD,
the response to ACEA was also attenuated. If it is
assumed that ACEA is a selective CB1 agonist, then the
most likely explanation for this would be a CB1 antago-
nism by CBD as has been reported in some studies (Per-
twee 2008). Furthermore, the inability of AM251 to
further prevent ACEA-induced depressor response in the
presence of CBD could be through competition with
AM251 for the CB1 receptor site, since AM251 has a simi-
lar binding affinity at CB1 (Ki 7.5 nmol/L; Lan et al.
1999) to that reported for CBD. However, an alternative
explanation could be that, since ACEA exerts agonist
activity at GPR55 in the nanomolar range, and CBD is an
antagonist at this receptor, the effects of ACEA may in
fact be mediated by both receptors rather than through
CB1 alone. In support of this, assuming a total blood vol-
ume of ~20 mL in a 300 g rat, the dose of ACEA admin-
istered (3 mg kg1; MW 365.98 g) would be expected to
achieve a total (although not necessarily free) blood con-
centration in the region of 100–120 nmol/L, which is
close to the EC50 (78 nmol/L) for ACEA activity at
(A) (B)
(D)
(E) (F)
(C)
Figure 4. Blood pressure and heart rate responses to O-1602 (5–100 ng kg1) in normotensive anesthetized rats (A and C) and WT mice (B and
D). Baseline MABP’s and HR’s for each group were SD rats (133  2 mmHg and 433  9 bpm; n = 8) andWT mice (90  3 mmHg and
334  6 bpm; n = 8), respectively. Panels (E and F) show the area above the curve (arbitrary units) for the blood pressure response in rats and
mice respectively. Values shown are mean  SEM.
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GPR55 measured in the GTPcS-binding assay. Therefore,
in an attempt to determine whether GPR55 plays a role
in the depressor response to ACEA we studied the hemo-
dynamic responses in anesthetized WT and GPR55/
mice.
In contrast to our findings in rats we were not able to
demonstrate a depressor response to ACEA in anesthe-
tized WT mice, the most likely explanation being the
significant contribution of the drug vehicle to the
response, which was much more marked in mice despite
taking significant measures to limit injection artefacts fol-
lowing bolus administration. An alternative explanation is
a lack of either vascular CB1or GPR55 receptors in mouse
resistance vessels, although CB1 expression has recently
been shown in murine skeletal muscle arterioles (Szekeres
et al. 2012) and GPR55 has been shown to be expressed
(A) (B)
(D)(C)
Figure 5. Blood pressure and heart rate responses to O-1602 (5–20 mg kg1) in hypertensive SHR rats in the presence of vehicle (A); CBD
(5 mg kg1; B); AM281 (10 mg kg1; C); or a combination of CBD and AM281 (D). Baseline MABP’s and HR’s for each group were SHR
(146  5 mmHg and 305  10 bpm; n = 6); SHR & CBD (141  5 mmHg and 296  8 bpm; n = 6); SHR &AM281 (153  6 mmHg and
296  9 bpm; n = 7); and SHR & CBD& AM281 (151  5 mmHg and 297  12 bpm; n = 7), respectively. Values shown are mean  SEM.
Table 2. Hemodynamic responses to O-1602 in conscious hypertensive rats, pretreated with metoprolol (10 mg kg1 i.v.) to prevent baroreceptor
reflex correction of blood pressure, in the absence or presence of AM281 (10 mg kg1), CBD (5 mg kg1) or a combination of the two.
MABP [depressor response - area above the curve (arbitrary units)] Control +CBD +AM281 +CBD and AM281
Vehicle 22  19 – – –
O-1602 (5 mg kg1) 59  21 189  32* 196  44* 41  17
O-1602 (10 mg kg1) 56  22 23  17 160  31* 180  29*
O-1602 (20 mg kg1) 26  16 73  38 191  30* 199  29*
HR [tachycardic response – area under the curve (arbitrary units)] Control +CBD +AM281 +CBD and AM281
Vehicle 96  36 – – –
O-l602 (5 mg kg1) 61  24 68  11 39  11 53  22
O-1602 (10 mg kg1) 18  8 79  29 40  12 37  32
O-1602 (20 mg kg1) 72  13 98  32 56  26 38  16
Baseline MABP’s and HR’s for each group were control (146  5 mmHg and 305  10 bpm; n = 6); CBD (141  5 mmHg, 296  8 bpm;
n = 6); AM281 (153  6 mmHg and 296  9 bpm; n = 7); and CBD and AM281 (151  5 mmHg and 297  12 bpm; n = 7). Values shown
are mean  SEM of the area above/below the curve. *P < 0.05 compared to the same dose in controls. *P < 0.05 versus equivalent 0-1602 dose
in control group.
2015 | Vol. 3 | Iss. 3 | e00143
Page 10
ª 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Hemodynamic Profiling of Cannabinoid Ligands S. K. Walsh et al.
in mouse arteries (Daly et al. 2010). Therefore, whether
or not ACEA induces a vasodepressor response, at least in
part, through GPR55 remains to be confirmed.
Hemodynamic responses to O-1602
The second major finding of this study was that, on its
own, O-1602 did not induce any changes in BP in nor-
motensive rats or mice, regardless of whether they were
anesthetized or in the conscious state. In light of reports
that responses to some cannabinoids are only evident
(Wheal et al. 2007) or are exaggerated (Ho and Gardiner
2009) in the presence of hypertension, we tested O-1602
in conscious hypertensive rats, but again found no mea-
surable response. However, in conscious hypertensive rats
coadministration of the selective CB1 antagonist AM281
revealed a marked fall in arterial pressure in response to
O-1602, while in conscious WT mice pretreated with
CBD, and in CB1
/ mice, the highest dose of O-1602
also elicited a depressor response. Taken together these
findings suggest that, whatever receptor O-1602 is acting
through, it appears to be under CB1-mediated inhibition
under normal physiological conditions. Although there is
increasing evidence that GPR18 is an important receptor
target for O-1602 (McHugh et al. 2010), the finding that
we could not observe a response to O-1602 in the pres-
ence of a CB1 receptor antagonist in GPR55
/ mice,
combined with the data from the GTPcS activation assay
that demonstrated agonist activity of O-1602 at rat and
mouse GPR55, suggests that the receptor mediating the
depressor response to O-1602 is indeed GPR55. This is in
contrast to a study using abnormal cannabidiol (abn-
CBD), of which O-1602 is a synthetic analog and has
similarly been described as both a GPR55 and GPR18
agonist, in which it was shown to induce a marked
vasodepressor response on its own in both WT and
GPR55/ mice, leading to the conclusion that GPR55
does not mediate the depressor responses to abn-CBD
(Johns et al. 2007). However, if O-1602 and abn-CBD
share a similar profile of activity at GPR55 and GPR18,
how can the discrepancy between our findings with O-
1602 and with abn-CBD be resolved? One simple explana-
tion may be due to injection artefacts induced by the
drug vehicle, since in our mice we have taken account of
this in measuring the responses to each cannabinoid
ligand. In the case of O-1602 we found that the vehicle
produced a fall in arterial BP that was indistinguishable
from the response to O-1602. In the study by Johns et al.
(2007), however, they did not report any data for vehicle-
control responses and therefore it is possible that the
responses they reported were exaggerated by a vehicle
effect. Alternatively, while various compounds have been
shown to activate GPR18 they exhibit biased agonism in
terms of the downstream signaling pathways that are acti-
vated (Console-Bram et al. 2014) and that, at least in a
cell line stably expressing GPR18, O-1602 and abn-CBD
exhibit different patterns of GPR18 activation. Therefore,
the signaling pathways that elicit the relaxation of vascu-
lar smooth muscle in response to GPR55 activation may
differ between abn-CBD and O-1602.
Responses to AM251
AM251 on its own produced a small and transient, but
significant, depressor response in both anesthetized rats
and WT mice. This is the first report of a vasodepressor
response to AM251 in vivo, but a recent report has
shown AM251 to increase coronary flow in rat isolated
hearts (Andrag and Curtis 2013). It is unlikely that this
response to AM251 is due to CB1 receptor blockade, since
Table 3. Depressor responses to O-1602 in conscious WT and CB1
/mice pretreated with metoprolol to remove baroreceptor reflex correction
of blood pressure.
MABP [depressor response - area above the curve (arbitrary units)] Control +CBD +AM281 +CBD and AM281
Vehicle 99.5  17.8 – 69.5  5.7 –
O-1602 (5 mg kg1) 91.9  38.2 99.6  25.8 64.6  17.5 73.3  24.5
O-1602 (10 mg kg1) 44.1  9.6 73.5  17.8 95.2  6.5 114.6  17.6
O-1602 (15 mg kg1) 61.3  10.9 148.9  17.1† 101.5  4.1* 119.7  18.1
HR [bradycardic response - area above the curve (arbitrary units)] Control +CBD +AM281 +CBD & AM281
Vehicle 44.4  12.2 – 67.7  4.9 –
O-1602 (5 mg kg1) 41.1  20.8 17.4  11.7 55.3  20.9 154.8  61.7
O-1602 (10 mg kg1) 48.7  25.4 186.8  42.1† 130.5  20.5* 298.2  111.7
O-1602 (15 mg kg1) 95.3  6.5* 197.1  17.1† 183.1  50.9* 286.6  105.4
Responses were determined in the absence and presence of CBD (5 mg kg1). Baseline MABP’s and HR’s for each group were: WT
(128  4 mmHg and 485  9 bpm; n = 5); CB1/ (134  2 mmHg and 438  5 bpm; n = 5); WT and CBD (122  3 mmHg and
384  6 bpm; n = 6); and CB1/ and CBD (135  3 mmHg and 477  5 bpm; n = 6). Values are mean  SEM.
*P < 0.01 versus vehicle control (within group); †P < 0.01 versus equivalent dose in WT mice.
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inhibition of any constitutive CB1 activity in controlling
vascular tone would be expected to increase, rather than
decrease, BP and that the response would be prolonged.
However, the data from the GTPcS-binding assay in the
present studies show that in both rat and mouse mem-
branes expressing GPR55, AM251 has agonist activity
with EC50 values in the nanomolar range, lending support
to other studies showing that AM251 acts as a GPR55
agonist (Ryberg et al. 2007; Kapur et al. 2009). At the
doses of AM251 used in the present study (1 and
3 mg kg1; MW 555.24 g), an approximate blood con-
centration of 60–70 nmol/L would be achieved, which
(A) (B)
(D)
(E) (F)
(G) (H)
(C)
Figure 6. Blood pressure (left hand panels) and heart rate (right hand panels) responses to O-1602 (5–20 mg kg1) in normotensive conscious
mice in the absence and presence of CBD (5 mg kg1). Baseline MABP’s and HR’s for each group were WT (128  4 mmHg and 485  9 bpm;
n = 5; Panels A and B); CB1
/ (134  2 mmHg and 438  5 bpm; n = 5; Panels C and D); WT with CBD (122  3 mmHg and 384  6 bpm;
n = 6; Panels E and F); and CB1
/ with CBD (135  3 mmHg and 477  5 bpm; n = 6; Panels G and H). Values shown are mean  SEM.
Values for areas above/under the curve are shown in Table 3.
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equates approximately to the EC50 values from the GTPcS
assay. Therefore, it is not unreasonable to suggest that the
depressor response to AM251 is mediated via GPR55.
Indeed, in support of this we observed a blunted response
to AM251 in GPR55/ mice, although the larger (but
not statistically significant) vehicle effect in this strain of
mice means that this observation should be interpreted
with caution.
In an attempt to further establish a role for GPR55 in
mediating the response to AM251, we attempted to block
the response to AM251 with CBD. However, instead of
an inhibition of the response to AM251 we saw an
enhanced response implying that an action of CBD at a
different receptor site (possibly CB1) is somehow unmask-
ing further the GPR55-stimulating effect of AM251.
Indeed, there is increasing evidence of coexpression and
“cross-talk” between cannabinoid receptors (reviewed in
Pertwee et al. 2010) that supports the notion that ligands
binding to the CB1 receptor could influence the response
to ligands acting through GPR55, and vice versa. For
example, expression of both CB1 (Hogestatt and Zyg-
mund 2002) and GPR55 (Daly et al. 2010) receptors has
been shown in vascular smooth muscle and endothelium,
which may lead to possible receptor dimerization. In
terms of receptor cross-talk, GPR55 signaling is inhibited
in the presence of CB1, while CB1 receptor signaling is
enhanced when GPR55 is coexpressed in the same cells
(Kargl et al. 2012). It has similarly been shown in endo-
thelial cells that when CB1 and GPR55 receptor integrins
are un-clustered, the intracellular signaling pathway acti-
vated by AEA are different from those activated when the
integrins are clustered, due to CB1 receptor uncoupling
(Waldeck-Weiermair et al. 2008). In vitro functional evi-
dence to support this concept arises from observations
that some cannabinoid ligands (including AM251 and ri-
monabant) can either inhibit or enhance the downstream
signaling following activation of GPR55 by lysophosphat-
idylinositol (LPI), now regarded as the endogenous ligand
for GPR55 (Kotsikorou et al. 2011). Our current study is,
we believe, the first functional in vivo evidence of an
(A) (B)
(D)
(E)
(C)
Figure 7. Hemodynamic responses to CBD (50 lg kg1) and its vehicle in normotensive anesthetized rats (A and B) and WT and GPR55/ mice
(C–E). Baseline MABP’s and HR’s for each group were SD Rat (135  4 mmHg and 390  4 bpm; n = 8); WT (86  3 mmHg and
323  4 bpm; n = 8); and GPR55/(87  4 mmHg and 329  5 bpm; n = 8), respectively. Values shown are mean  SEM. *P < 0.05
compared to vehicle response.
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interaction of this nature, at least in terms of cardiovascu-
lar hemodynamics, and if CBD is indeed acting as an
inhibitor at CB1 then altered signaling could explain the
enhanced response to GPR55 activation by AM251.
Although the principal purpose of this study was to
profile the various ligands for their action at CB1 and
GPR55 receptors to induce a depressor response, we did
make some observations that may help to understand the
role that CB1 and GPR55 play in physiological cardiovas-
cular control. For example, the effects of O-1602 on HR
in conscious WT mice, while on the basis of the observed
pharmacology of this compound cannot be attributed to
an action at GPR55, is nevertheless intriguing. When
given alone, O-1602 caused a small, but significant, bra-
dycardia at the highest dose tested, however, when mice
were pretreated with CBD this bradycardic response was
markedly exaggerated and evident at much lower doses;
an enhanced response to O-1602 was also seen in CB1
/
mice, suggesting that CBD may be acting as a CB1 antag-
onist. However, rather than having no effect in the
absence of the CB1 receptor, CBD blunted the O-1602
response in CB1
/ mice, suggestive that in the absence
of CB1, CBD is acting at an additional site. A reduced HR
could be either through a direct action on the sinoatrial
node, or through interference with cardiac sympathetic
control, either through central or peripheral sites. We
have found no reports of direct actions of cannabinoid
ligands on the pacemaker cells of the heart, but cannot
rule this out as a site of action. However, since the brady-
cardic response was only observed in conscious animals,
it is likely to be mediated by alterations in autonomic
cardiovascular control as it is well documented that
(A) (B)
(D)
(E)
(C)
Figure 8. Hemodynamic responses to AM251 (1 and 3 mg kg1) in the absence and presence of CBD (50 lg kg1) in normotensive
anesthetized rats (A and B) and WT and GPR55/ mice (C-E). Baseline MABP’s and HR’s for each group of rats were AM251 alone
(123  5 mmHg and 338  6 bpm; n = 7); CBD and AM251 (131  2 mmHg and 350  5 bpm; n = 8), respectively. Baseline MABP’s and
HR’s for each group of WT mice were AM251 alone (87  4 mmHg and 329  6 bpm; n = 8); CBD and AM251 (86  3 mmHg and
323  4 bpm; n = 8), respectively. Baseline MABP’s and HR’s for each group of GPR55/ mice were AM251 alone (89  3 mmHg and
339  5 bpm; n = 8) and CBD and AM251 (87  3 mmHg and 329  5 bpm; n = 8), respectively. Values shown are mean  SEM. *P < 0.05
compared to vehicle response.
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anesthesia itself suppresses cardiac sympathetic outflow.
Cannabinoids can suppress sympathetic outflow from the
nucleus tractus solitarius (NTS) by a CB1 and GABA-
mediated mechanism (Seagard et al. 2004; Brozoski et al.
2005) and have been demonstrated to induce cardiovas-
cular depression through a combination of both decreased
sympathetic and increased vagal outflow (Niederhoffer
et al. 2003). Although it remains to be determined
whether an action of O-1602 at GPR18 is responsible for
producing the bradycardic response, a recent study has
demonstrated an important central role for GPR18 in BP
control (Penumarti and Abdel-Rahman 2014). However,
in light of the fact that CB1 antagonism or receptor
knockout markedly enhanced the depressive effect of O-
1602 on HR, the modulation of the central cardiovascular
control centers by cannabinoids may involve an intricate
balance between the activities of different receptors.
We also observed that baseline BPs were higher in con-
scious (but not anesthetized) GPR55/ (165  2 mmHg)
compared to WT (128  4 mmHg; P < 0.01) mice,
implying a role for this receptor in normal physiological
cardiovascular control and that a fully functioning sympa-
thetic tone is required to see this effect. We also observed
that metoprolol, which was used to prevent excessive
baroreceptor reflex-mediated correction of BP responses
in conscious animals, induced a profound and long-lasting
bradycardia in the conscious GPR55/ mice, suggesting
that in these animals there is an upregulated parasympa-
thetic tone that occurs either as a compensatory mecha-
nism in response to the increased basal arterial pressure,
or through a loss of some GPR55-mediated contribution
to central cardiovascular control. Although GPR55 is
widely distributed in the brain, in particular the caudate
nucleus and the putamen (Sawzdargo et al. 1999), thus far
there have been no reports of GPR55 expression in the
NTS; therefore, it is not possible to speculate to any great
extent as to whether or not central GPR55 receptors play a
role in cardiovascular control. Second, the raised BP
(presumably due to increased peripheral resistance) and
profound response to withdrawal of cardiac b-adrenocep-
tor stimulation may be indicative of an altered (height-
ened) sensitivity of adrenoceptors, suggestive of some
interaction between these receptors and GPR55. Indeed,
we have recently shown that GPR55/ mice exhibit a
reduced inotropic response to b-adrenoceptor stimulation
(Walsh et al. 2014). Clearly, therefore, the potential role of
GPR55 in cardiovascular control requires further detailed
study.
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